Table 4 Grade 3 to 4 toxicities during chemotherapy in the 3 treatment groups
Treatment Group | Bevacizumab+ Platinum | Platinum (reference) | Monotherapy |
|---|---|---|---|
All toxicities, n (%) | 8 (50.0) | 14 (35.9) | 3 (15.8) |
Peripheral neuropathy, n (%) | 3 (18.8) | 5 (12.8) | 0 (0.0) |
Neutropenia, n (%) | 2 (12.5) | 8 (20.5) | 2 (10.5) |
General fatigue, n (%) | 2 (12.5) | 1 (2.6) | 0 (0.0) |
Gastrointestinal perforation, n (%) | 0 (0.0) | 1 (2.6) | 0 (0.0) |